Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ina Oehme

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
NPJ Precision Oncology|June 17, 2026
Integration and validation of complementary ex vivo assays for functional precision oncologyAnna Loboda, Jasmina Paluncic, Micaela Freitas, et al.
Journal of the American Chemical Society|October 6, 2022
Aza-SAHA Derivatives Are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 KnockoutRaphael R Steimbach, Corey J Herbst-Gervasoni, Severin Lechner, et al.
Acta Neuropathologica|August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatTill Milde, Susanne Kleber, Andrey Korshunov, et al.
Cancer Research|January 15, 2014
GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3Johannes Fabian, Marco Lodrini, Ina Oehme, et al.
Leukemia|April 29, 2025
The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cellsAndreas O Mieland, Giuseppe Petrosino, Mario Dejung, et al.
Oncotarget|December 22, 2016
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testingFlorian Selt, Juliane Hohloch, Thomas Hielscher, et al.
Scientific Reports|April 10, 2026
Ependymoma group-specific blood-brain barrier differences uncovered by a multi-omics approachJulia K Sundheimer, Julia Benzel, Aniello Federico, et al.
Neuro-Oncology|August 22, 2020
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastomaJonas Ecker, Venu Thatikonda, Gianluca Sigismondo, et al.
Journal of Neuro-Oncology|May 14, 2023
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cellsGintvile Valinciute, Jonas Ecker, Florian Selt, et al.
Cancers|February 15, 2022
Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft ModelsCharlotte Gatzweiler, Johannes Ridinger, Sonja Herter, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
NPJ Precision Oncology|June 17, 2026
Integration and validation of complementary ex vivo assays for functional precision oncologyAnna Loboda, Jasmina Paluncic, Micaela Freitas, et al.
Journal of the American Chemical Society|October 6, 2022
Aza-SAHA Derivatives Are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 KnockoutRaphael R Steimbach, Corey J Herbst-Gervasoni, Severin Lechner, et al.
Acta Neuropathologica|August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatTill Milde, Susanne Kleber, Andrey Korshunov, et al.
Cancer Research|January 15, 2014
GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3Johannes Fabian, Marco Lodrini, Ina Oehme, et al.
Leukemia|April 29, 2025
The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cellsAndreas O Mieland, Giuseppe Petrosino, Mario Dejung, et al.
Oncotarget|December 22, 2016
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testingFlorian Selt, Juliane Hohloch, Thomas Hielscher, et al.
Scientific Reports|April 10, 2026
Ependymoma group-specific blood-brain barrier differences uncovered by a multi-omics approachJulia K Sundheimer, Julia Benzel, Aniello Federico, et al.
Neuro-Oncology|August 22, 2020
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastomaJonas Ecker, Venu Thatikonda, Gianluca Sigismondo, et al.
Journal of Neuro-Oncology|May 14, 2023
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cellsGintvile Valinciute, Jonas Ecker, Florian Selt, et al.
Cancers|February 15, 2022
Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft ModelsCharlotte Gatzweiler, Johannes Ridinger, Sonja Herter, et al.
Pageof 9